Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.73 |
| ▸ | MEN1 | O00255 | 5/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | FAAH | O00519 | 1/20 | 0.62 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.59 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049371 | 0.85 | KDM4E (0.70) | KMT2AKDM4EMEN1TP53MAPK1 | |
| SCHEMBL1600111 | 0.83 | KMT2A (0.65) | KMT2AKDM4EMEN1TP53MAPK1 | |
| SCHEMBL19002673 | 0.83 | KDM4E (0.75) | KMT2AKDM4EMEN1TP53MAPK1 | |
| SCHEMBL19002677 | 0.82 | KMT2A (0.66) | KMT2AKDM4EMEN1TP53MAPK1 | |
| SCHEMBL20665217 | 0.81 | ALDH1A1 (0.74) | KMT2AKDM4EMEN1FAAHALDH1A1 | |
| SCHEMBL8225348 | 0.78 | KMT2A (0.58) | KMT2AKDM4EMEN1TP53MAPK1 | |
| SCHEMBL18182316 | 0.77 | MAPK1 (0.72) | KMT2AKDM4EMEN1TP53MAPK1 | |
| SCHEMBL3917099 | 0.77 | ALDH1A1 (0.51) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL2601932 | 0.77 | KMT2A (0.57) | KMT2AKDM4EMEN1TP53MAPK1 | |
| SCHEMBL13546095 | 0.77 | KDM4E (0.94) | KMT2AKDM4EMEN1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | SHY Therapeutics LLC | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | MAPK1, MAPK6, MAP3K1 | KMT2A 3181/4885KDM4E 3018/4885MEN1 3536/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | KMT2A 3544/4885KDM4E 3392/4885MEN1 4080/4885 |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | KMT2A 2512/4885KDM4E 1755/4885MEN1 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.